WEX Pharmaceuticals Inc.




#420 – 1090 West Pender Street

Vancouver BC

V6E 2N7


Member Sector: Biopharmaceuticals 

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. Our strategy is to derive drugs from naturally occurring toxins and develop products for the global market. WEX, headquartered in Vancouver, is a subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”), listed on The Stock Exchange of Hong Kong Limited (stock code: 0775). CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing and selling of environmental and human health products, as well as water businesses and investment in various financial and investment products. CKLS is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com. Business Objective We welcome the opportunity for partnerships that are based on shared visions, values, knowledge and expertise. This sharing adds value for each partner and paves the way to developing breakthrough drugs that provide solutions for unmet patient needs. Technology WEX is developing a new class of non-opioid analgesics. The Company’s proprietary product is HalneuronTM (tetrdotoxin, TTX), a small molecule, has been shown to be a safe, non addictive, well-tolerated, possible alternative to opioids. HalneuronTM is a new class of analgesic with a novel mechanism of action. It is a highly selective sodium channel blocker that targets voltage gated sodium channels on neurons but not those on cardiomyocytes. It is known to block nerve impulses that conduct pain signals. A Phase III clinical trial on the treatment of cancer related pain using HalneuronTM has recently been completed. We are in the process of filing a NDS with Health Canada for marketing approval. HalneuronTM has also been studied in a completed Phase II trial for chemotherapy induced neuropathic pain (CINP) in the US. WEX has conducted 15 clinical trials with HalneuronTM, with more than 700 patients treated to date. HalneuronTM is non-narcotic, without the side effects of opioids. It is non-addictive and has shown no evidence of tolerance. Clinical trials have shown that HalneuronTM provides a long duration of analgesia after an initial course of treatment in moderate to severe neuropathic pain.